Single Cell Acute Leukemia Analysis
Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Mar 26, 2025
Trial Information
Current as of July 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Single Cell Acute Leukemia Analysis, is focused on understanding why some patients with acute myeloid leukemia (AML) experience relapses after treatment. Researchers believe that certain genes, which help cancer cells resist the effects of treatments like chemotherapy, might be working together in the same cells. By studying samples from patients whose AML has come back, the team hopes to confirm this idea and learn more about how these genes behave, especially after exposure to chemotherapy.
To participate in this study, you must be an adult who has been informed about the trial and agrees to take part. You should also have relapsed or refractory (meaning your cancer has not responded to previous treatments) acute myeloid leukemia, regardless of what treatments you've had before. The trial is not yet recruiting participants, but if you qualify, you can expect to provide single-cell samples for analysis, which will help improve our understanding of AML and potentially lead to better treatment options in the future. It’s important to note that if you don’t speak French and a translator isn’t available, you may not be able to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patient
- • Patient who has received information about the study and has not expressed opposition,
- • Patients who are beneficiaries of a social security plan,
- • Patient with relapsed or refractory acute myeloid leukemia, whatever the previous treatment, the therapeutic line and the time between the previous treatment and the relapse.
- Exclusion Criteria:
- • Persons who do not understand the French language if there is no translator available to translate for them.
- • Absence of circulating blastosis.
About Assistance Publique Hopitaux De Marseille
Assistance Publique - Hôpitaux de Marseille (AP-HM) is a leading public healthcare institution in France, dedicated to providing high-quality medical care and advancing research in various clinical fields. As a prominent sponsor of clinical trials, AP-HM is committed to fostering innovation and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary approach, the institution collaborates with a network of healthcare professionals, researchers, and academic partners to facilitate cutting-edge studies that address critical health challenges. AP-HM's dedication to ethical standards and patient safety underscores its role as a trusted leader in clinical research and healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Régis Costello, Professor
Principal Investigator
Assitance Public - Hôpitaux de Marseille
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported